Connect Biopharma is trading at $2.26 (+5.7%) in pre-market, rebounding from Friday’s mild decline despite a lack of fresh company-specific news.

  • The gain likely reflects light pre-market trading and thin extended-hours liquidity rather than fundamental developments.
  • Broadly positive risk sentiment is supporting the move as U.S. equity futures and major indices trade higher.
  • No new headlines, earnings reports, or analyst calls have been issued since the stock's previous after-hours move on July 24.